WhiteLab Genomics Closes €23.2 Million Series B to Push AI Deeper Into Drug Discovery
The Paris-based startup has secured fresh capital to expand AI-driven genomics workflows — a signal that European biotech is staking serious money on machine-learning as a core discovery engine, not a bolt-on.
The Round and Who Backed It
On October 6, 2026, WhiteLab Genomics announced it had closed a €23.2 million Series B. The round was led by AVP, with Yadav Health, Blast Club, Omnes Capital, and Debiopharm Innovation Fund participating. That investor mix is worth reading carefully — Debiopharm's presence links WhiteLab to a pharma-adjacent ecosystem that cares about translational outcomes, not just platform narratives. Omnes and Blast Club bring a hybrid of deep-tech and growth-stage sensibility. AVP leading is the loudest signal: it puts institutional conviction behind the thesis that AI applied to genomics workflows can materially compress the front end of drug discovery.
What the company does, in plain terms, is apply AI to genomics and drug-discovery workflows — helping teams move faster from biological question to candidate. The details of specific pipeline assets or therapeutic focus were not disclosed in reporting. What is disclosed is the capital commitment, and €23.2 million at Series B is a meaningful number for a Paris-based life-sciences AI company.
Why European Biotech Is Paying Attention
The geography matters. Paris has spent the better part of a decade trying to position itself as a credible deep-tech hub, and WhiteLab is one of the more concrete data points in that argument. A Series B of this size, led by an institutional investor, with pharma-ecosystem participation, is not routine for French biotech. It suggests the company has shown enough — in capability, in workflow integration, in early results — to move past the exploratory stage.
The broader context is a funding environment that has been selective. Life-sciences AI saw a wave of early enthusiasm, followed by harder questions about what the AI actually does versus what it claims to do. Investors who stayed active through that correction are deploying with more discipline. The fact that Debiopharm Innovation Fund — an arm with direct proximity to clinical-stage concerns — is in this round implies WhiteLab's platform has been evaluated against real drug-development criteria, not just benchmark performance on public datasets.
It is also worth noting what this round is not. It is distinct from other AI drug-discovery financings covered separately — this is a standalone Paris company with its own stack, its own investor base, and its own trajectory.
What the Capital Is For
The financing was reported without a detailed breakdown of deployment plans. What can be inferred is structural: a Series B typically funds the transition from proving the platform to scaling its use — more partnerships, more internal pipeline investment, or both. For a company operating at the intersection of genomics and AI, that could mean expanding the data infrastructure that gives the models signal, deepening integrations with pharma partners, or hiring the computational biology and ML talent required to push from proof-of-concept to repeatable discovery outcomes.
The participation of multiple investors with different mandates — growth-stage venture, pharma innovation funds, deep-tech backers — suggests WhiteLab is being positioned for multiple types of value creation simultaneously: licensing, co-development, and potentially platform-as-a-service arrangements with larger industry players.
The Bigger Shift
What WhiteLab's €23.2 million round represents, set against the current landscape, is the normalization of AI as infrastructure in drug discovery — not as a moonshot bet but as a funded, institutionally backed operating assumption. The question is no longer whether AI belongs in genomics workflows. It is which companies have built the right combination of proprietary data access, model architecture, and scientific credibility to become durable platforms rather than features absorbed by larger players.
For founders and operators watching this space, the signal is clear: the capital is moving toward teams that can demonstrate AI doing specific, measurable work inside discovery pipelines — not teams promising general intelligence applied to biology in the abstract. WhiteLab's Series B is one more data point in that consolidation.